You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

651 Results
Document
Jul 2018
Document
Jul 2018
Document
Jul 2018
Document
Jul 2018
Document
Aug 2018
Regimen
Cancer Type:
Hematologic, 
Lymphoma - T-cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Pralatrexate - Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
PRALAtrexate,
leucovorin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2023
Document
Aug 2018
Guidelines and Advice
Status: Current
ID: pet 2018-1
Version: n/a
Oct 2018
Drug
Other Name(s): Alunbrig®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jul 2024
Document
Nov 2018
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    brigatinib - For the treatment of anaplastic lymphoma kinase-positive locally advanced or metastatic non-small cell lung cancer according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
brigatinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jul 2024
Document
Nov 2018

Pages